Rezende R, León Higuera J G, Manent L, Lewis K, Angulo O
Clínica Ortopédica Especializada de Governador Valadares, Governador Valadares, Brazil.
Department of Sports Medicine and Rehabilitation, The San José Children's University Hospital, Fundacion Universitaria de Ciencias de la Salud, Bogotá D.C., Colombia.
Front Med Technol. 2025 Mar 18;7:1513155. doi: 10.3389/fmedt.2025.1513155. eCollection 2025.
To evaluate the effectiveness of the Atlasprofilax intervention in the treatment of chronic cervicobrachialgia in a cohort of 162 patients. The assessment focused on measuring pain reduction, overall patient satisfaction, and improvements in the range of motion of the neck and the affected upper-limb.
A retrospective, open-label, qualitative-quantitative longitudinal cut study was conducted in an orthopedic medical center in Brazil from June 2016 to July 2017. A total of 162 Brazilian patients with diagnosed chronic cervicobrachialgia were treated with a single session of non-invasive device-mediated treatment (Atlasprofilax method) that utilizes mechanotransductive vibropercussion on the suboccipital myofascia for approximately eight minutes. Patient conditions were established at baseline, and three follow-up assessments were conducted at 1, 6, and 9 months after treatment to evaluate the endpoints. Primary endpoints included changes in the cervical VAS pain and brachial VAS pain, while secondary endpoints included changes in the range of motion of the neck and affected upper limb, as well as patient satisfaction. A single blinded examiner conducted the evaluations at baseline and follow-up assessments, and the intervention was performed by an orthopedic doctor specializing in shoulder surgery.
The primary endpoints showed a significant reduction in pain. The mean cervical VAS pain score at baseline was 7.15 ± 2.15 [median VAS 8 (6;8)], which reduced to 1.47 ± 1.04 [median 0.5 (0/2)] at month 9 [mean reduction -5.67 ± 2.30 and median -6 (-7/-4), < 0.0001]. Fifty percent of the patients reported no pain on the VAS at the 9-month follow-up. The mean brachial VAS pain score at baseline was 6.16 ± 2.31 [median 6 (3;8)], which reduced to 0.33 ± 1.79 [median 0 (0;2)] at month 9 [mean reduction -5.83 ± 2.35; median reduction -6 (-8/-4), < 0.0001]. At the 9-month follow-up, 88.89% of patients reported no brachial pain on the VAS. Secondary endpoints indicated a marked improvement in the average range of motion of the neck and upper limb in all subtypes of measurements. Additionally, 87.04% of patients reported satisfaction with the therapy and an improvement in their daily activities. No side-effects were observed.
AtlasProfilax is nowadays a good option as an intervention when it comes to pain control and activities of daily living.
评估Atlasprofilax干预措施对162例慢性颈臂痛患者的治疗效果。评估重点在于测量疼痛减轻程度、患者总体满意度，以及颈部和患侧上肢活动范围的改善情况。
2016年6月至2017年7月在巴西一家骨科医疗中心进行了一项回顾性、开放标签、定性-定量纵向横断面研究。共有162例诊断为慢性颈臂痛的巴西患者接受了单次非侵入性设备介导治疗（Atlasprofilax方法），该方法利用机械转导振动叩击枕下肌筋膜约8分钟。在基线时确定患者状况，并在治疗后1、6和9个月进行三次随访评估以评估终点指标。主要终点指标包括颈部视觉模拟评分法（VAS）疼痛和臂部VAS疼痛的变化，次要终点指标包括颈部和患侧上肢活动范围的变化以及患者满意度。一名单盲检查者在基线和随访评估时进行评估，干预由一名专门从事肩部手术的骨科医生进行。
主要终点指标显示疼痛显著减轻。基线时颈部VAS疼痛平均评分为7.15±2.15[VAS中位数8（6；8）]，在第9个月降至1.47±1.04[中位数0.5（0/2）][平均减轻-5.67±2.30，中位数-6（-7/-4），P<0.0001]。50%的患者在9个月随访时报告VAS上无痛。基线时臂部VAS疼痛平均评分为6.16±2.31[中位数6（3；8）]，在第9个月降至0.33±1.79[中位数0（0；2）][平均减轻-5.83±2.35；中位数减轻-6（-8/-4），P<0.0001]。在9个月随访时，88.89%的患者报告VAS上无臂部疼痛。次要终点指标表明在所有测量亚型中颈部和上肢的平均活动范围均有显著改善。此外，87.04%的患者报告对治疗满意且日常活动有所改善。未观察到副作用。
就疼痛控制和日常生活活动而言，如今AtlasProfilax作为一种干预措施是一个不错的选择。
